Nomura/Instinet analyst Christopher Marai weighed in on Alnylam Pharmaceuticals (NASDAQ: ALNY) after competitor Silence Therapeutics (SLN) announced notice of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE